Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

Nobuya InagakiKyoto University Graduate School of Medicine, Department of Diabetes, Endocrinology and Nutrition, Kyoto, Japan

Kazuoki KondoMitsubishi Tanabe Pharma Corporation, 17-10 Nihonbashi-Koamicho, Chuo-ku, Tokyo, Japan+81 3 6748 7693; +81 3 3663 6258; [email protected]

Toru YoshinariMitsubishi Tanabe Pharma Corporation, 17-10 Nihonbashi-Koamicho, Chuo-ku, Tokyo, Japan+81 3 6748 7693; +81 3 3663 6258; [email protected]

Nahoko TakahashiMitsubishi Tanabe Pharma Corporation, 17-10 Nihonbashi-Koamicho, Chuo-ku, Tokyo, Japan+81 3 6748 7693; +81 3 3663 6258; [email protected]

Yutaka SusutaMitsubishi Tanabe Pharma Corporation, 17-10 Nihonbashi-Koamicho, Chuo-ku, Tokyo, Japan+81 3 6748 7693; +81 3 3663 6258; [email protected]

Hideki KukiMitsubishi Tanabe Pharma Corporation, 17-10 Nihonbashi-Koamicho, Chuo-ku, Tokyo, Japan+81 3 6748 7693; +81 3 3663 6258; [email protected]

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date